Straits Times Index
3,272.72 +47.55 (+1.47%) S&P 500
5,070.55 +59.95 (+1.20%) Dow
38,503.69 +263.71 (+0.69%) Nasdaq
15,696.64 +245.33 (+1.59%) Bitcoin USD
66,451.33 -259.16 (-0.39%) CMC Crypto 200
1,428.97 +14.21 (+1.01%)
Bausch Health Companies Inc. (BHC)
After hours:
| Previous close | 8.45 |
| Open | 8.50 |
| Bid | 8.50 x 1400 |
| Ask | 8.51 x 3000 |
| Day's range | 8.43 - 8.62 |
| 52-week range | 5.57 - 11.46 |
| Volume | |
| Avg. volume | 2,778,543 |
| Market cap | 3.128B |
| Beta (5Y monthly) | 0.86 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 10 Nov 2010 |
| 1y target est | N/A |
- Insider Monkey
10 Best Healthcare Stocks to Buy Under $20
In this article, we will be taking a look at the 10 best healthcare stocks to buy under $20. To skip our detailed analysis of the healthcare sector, you can go directly to see the 5 Best Healthcare Stocks to Buy Under $20. Global Healthcare Outlook for 2024 As 2024 progresses, the optimism surrounding the healthcare […]
- Reuters
Bausch wins US appeal to block Alvogen generic of diarrhea drug
A U.S. appeals court on Thursday affirmed a decision for Bausch Health that barred rival drugmaker Alvogen from marketing a proposed generic version of Bausch's diarrhea treatment Xifaxan until 2029. A Delaware federal court had determined that Alvogen subsidiary Norwich Pharmaceuticals' generic would infringe patents owned by Bausch's Salix Pharmaceuticals.
- Zacks
Will Bausch (BHC) Beat Estimates Again in Its Next Earnings Report?
Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
